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esponsibility of InsAbstract A combination of melt-granulated dispersion and surface adsorption techniques
was used to enhance the dissolution and tableting properties of cefuroxime axetil (CA).
Gelucire 50/13 was used as the melt-dispersion carrier and Sylysia 350 was used to adsorb the
melt dispersion. Solubility studies showed an 8-fold increase in solubility at a ratio of 1:1.5 for
CA:Gelucire 50/13. The minimum quantity of Sylysia 350 required to achieve the desired
ﬂowability and compressibility was 0.5 parts of Sylysia 350 per unit of Gelucire 50/13. Phase
solubility studies showed negative DG0tr values for Gelucire 50/13 at various concentrations
(2–10%, w/v), indicating the spontaneous nature of solubilization. FT-IR and DSC spectra
exhibited drug-excipient compatibility. Molecular modeling by a computational method
employing energy minimization revealed entrapment of CA in Gelucire 50/13. The total
potential energy of CA (70.562 kcal/mol) was reduced to 33.578 kcal/mol after solid
dispersion with Gelucire 50/13. P-XRD studies indicated that the presence of Sylysia 350 isedica, Chinese Academy of Medical Sciences and Chinese Pharmaceutical Association. Production and
rved.
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Jammula Sruti et al.114less likely to promote the reversion of the amorphous CA to a crystalline state. In vitro
dissolution studies demonstrated an improved dissolution rate, and drug release at 15 min
(Q15min) exhibited a 15-fold improvement. The rapidly dissolving CA tablets showed
improved dissolution with improved tableting properties.
& 2013 Institute of Materia Medica, Chinese Academy of Medical Sciences and Chinese Pharmaceutical
Association. Production and hosting by Elsevier B.V. All rights reserved.1. Introduction
Drugs which belong to class II of the biopharmaceutical
classiﬁcation system (BCS) are characterized by high mem-
brane permeability, slow dissolution rate (due to low aqueous
solubility), and high peroral dose1. The solubility or dissolu-
tion rate of a drug in this category is therefore a key factor in
determining the rate and extent of its absorption. Enhance-
ment of the dissolution rate is vital to attain a suitable blood
concentration for therapeutic effect, as their dissolution rates
are typically the rate-limiting step for bioavailability. Cefur-
oxime axetil (CA) is an established broad spectrum b-lacta-
mase-stable cephalosporin with poor water solubility. It is
used orally for the treatment of mild to moderate respiratory
tract infections, acute bacterial otitis, pharyngitis, tonsillitis,
mild to moderate uncomplicated skin infections, and uncom-
plicated urinary tract infections2.
Several technological methods have been reported for improve-
ment of solubility and dissolution rate of poorly water-soluble
drugs, namely (a) reducing particle size to increase surface area; (b)
solubilization in surfactant systems; (c) formation of water soluble
complexes; (d) use of prodrug and drug derivatization approaches
such as strong electrolyte salt forms that usually have higher
dissolution rates; (e) lyophilization utilizing skimmed milk as a
carrier3; (f) manipulation of the solid state of the drug substance to
improve drug dissolution, i.e., by decreasing crystallinity of the
drug substance through formation of solid dispersions4. Solid
dispersion can be deﬁned as distribution of active ingredients in
molecular, amorphous, and/or crystalline forms surrounded by an
inert carrier. The solid state characteristics of solid dispersions
have been extensively studied and reported5,6. Formulation of
poorly water-soluble drugs as solid dispersions leads to a marked
improvement in their dissolution rates and is often accompanied
by an increase in their relative bioavailability7,8.
Recently, many researchers reported solid dispersions using
Gelucire (polyglycolized glyceride) by fusion and solvent
evaporation techniques9,10. Gelucire is a varying mixture of
mono, di and triglycerides with polyethylene glycol esters of
fatty acids. They are inert, semisolid and waxy amphiphilic
excipients. A low hydrophilic–lipophilic balance (HLB) value
in Gelucire decreases the dissolution rate whereas a high HLB
value enhances the dissolution rate. The low HLB compounds
are composed of partial glycerides while those with HLB
values above 10 are mixtures of partial saturated glycerides
and polyethylene glycol (PEG) esters. Gelucire 50/13 is a
semisolid excipient with an HLB value of 13 and melting point
of 50 1C. Its hydrophilic property makes it a good choice for
use as a carrier in preparation of solid dispersions by fusion
method11,12.Although Gelucire 50/13-based solid dispersions greatly
enhance the dissolution rate of poorly water soluble drugs,
they have some disadvantages such as poor ﬂow, poor
compressibility and difﬁculty in pulverization5. In order to
overcome these problems an inert material with good ﬂow
and compressibility may be used to adsorb the melt disper-
sion on its surface. Sylysia is an amorphous SiO2 with high
speciﬁc surface area and porosity and is generally recognized
as safe (GRAS) under United States FDA (Food and Drug
Administration) regulations. Sylysia 350 is a dry, white
micronized porous powder having an average particle size
of 3.9 mm, and is tasteless and odorless. It has a high speciﬁc
surface area (300 m2/g) and a high adsorption capacity
(310 mL/100 g), making it a good material for adsorption
of a high proportion of drug. It is used primarily as a tablet
excipient to improve the ease of powder ﬂow through the
tableting process, which provides more accurate dosages. It
can be also used for powderizing liquids, to increase the
viscosity of liquids and gels, or to protect sensitive com-
pounds from moisture. It is used in research as a drug carrier
in solid dispersions to improve dissolution13. Spray-drying
indomethacin and Sylysia resulted in an amorphous form of
indomethacin in a solid dispersion, probably due to its
incorporation into mesopores that inhibit crystallization of
the drug14. This amorphous structure was stable for at least 2
months at elevated temperature and humidity. Similar results
(dissolution rate improvement and amorphous drug structure
in the dispersion) were also obtained with tolbutamide and
spironolactone15.
Hence, the primary objective of the present research work
was to improve the solubility and dissolution rate of CA by
melt-dispersion granulation employing Gelucire 50/13 as a
meltable hydrophilic carrier. The secondary objective was to
convert the melt dispersion into ﬂowable and compressible
dispersion granules to yield a rapidly dissolving (more than
85% drug dissolution within 30 min) tablet formulation.2. Materials and methods
2.1. Materials
Cefuroxime axetil was a generous gift from Aurobindo Pharma
Ltd., India. Gelucire 50/13 was a generous gift from Gattefosse
India Pvt Ltd., India, and Sylysia 350 was a gift from Fuji
Silysia Chemicals, Japan. Crospovidone and Avicel PH 102
were purchased from M/s FMC Biopolymer (Mumbai, India).
All other chemicals and reagents used were of analytical grade.
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CA–polymer interactions were assessed by FT-IR spectro-
scopy. FT-IR spectra of selected CA and physical mixtures
(PM) and formulation A6 were recorded on IRAfﬁnity-1,
(Shimadzu, Japan) using KBr discs. The instrument was
operated under dry air purge and the scans were collected at
a scanning speed of 2 mm/s with resolution of 4 cm1 over the
region 4000–400 cm1.2.3. Differential scanning calorimetry (DSC) study
The DSC measurements were performed on a DSC-60
(Shimadzu, Japan) with a thermal analyzer. All samples
(about 1.25 mg of CA or equivalent) were placed in sealed
aluminum pans before heating under nitrogen ﬂow (20 mL/min)
at a scanning rate of 10 1C/min from 25 to 250 1C. An empty
aluminum pan was used as reference. DSC measurements were
also performed for Gelucire 50/13, PM and formulation A6 to
study the drug–polymer interaction.2.4. Analytical methods
In order to determine the solubility of the drug, standard
curves were prepared in simulated gastric ﬂuid (SGF) without
enzymes. The absorbance of the standard solutions prepared
in the concentration range of 5–40 mg/mL was measured at
lmax 280 nm using a UV–Vis spectrophotometer UV-1800
(Shimadzu, Japan).2.5. Phase solubility studies
Phase solubility determinations were performed as per a
standard method16. An excess amount of CA was placed in
a screw-cap glass vial to which 20 mL of distilled water
containing various concentrations (0%, 2%, 4%, 6%, 8%
and 10%) of Gelucire 50/13 was added (Table 1). The samples
were shaken at 3770.5 1C for 72 h on a mini rotary shaker
12R DX (Remi, India). After 72 h, the samples were ﬁltered
through a 0.45 mm membrane ﬁlter (Auroco, Thailand). The
ﬁltrate was diluted suitably and analyzed spectrophoto-
metrically.Table 1 Effect of gelucire 50/13 concentration and
Gibb’s free energy on CA solubility.
Concentration of
Gelucire 50/13
(%, w/v)
Concentration
of CA (mg/mL)
DGtr
1
(J/mol)a
0 0.1270.02 0
2 0.7870.03 0
4 0.8370.02 367
6 0.9970.01 789
8 1.1070.04 1062
10 1.1170.03 1169
aAll values are expressed as mean7SD, n¼6.The value of the apparent stability constant, Ks for CA–
Gelucire 50/13 combinations was computed from the phase-
solubility proﬁles, as described by
Ks¼ Slope=Interceptð1SlopeÞ ð1Þ
Gibb’s free energy of transfer (DG0tr) of CA from SGF without
enzyme to solutions of carrier was calculated as
DG0tr ¼ 2:303RT log
S0
Ss
 
ð2Þ
where S0/Ss is the ratio of the molar solubility of CA in SGF
(without enzyme) of Gelucire 50/13 to that in the same
medium without Gelucire 50/13.2.6. Conformational analysis by molecular modeling
The computer-aided molecular modeling approach was used
for conformational analysis of drug–polymer complexation
during dispersions. The molecular structures were drawn using
Chem Draw Ultra 11.0 software (Cambridgesoft, Cambridge,
MA 02140, USA) and 3D molecular models were generated
using Chem Bio 3D Ultra-11.0 software (Cambridgesoft,
Cambridge, MA 02140, USA). The drug–polymer complex
was architecturally prepared by docking in the software.
The energy minimization was carried out and total potential
energy of the pure drug and its complex was computed, which
gives an estimate of the total energy minimization and
conﬁrms the possibility of complex formation during disper-
sion. All calculations used are for geometric optimization.
All the energy minimizations were carried out until the RMS
gradient was less than 0.0817.2.7. Preparation of dispersion granules
Ternary dispersion granules were prepared using hot-melt
granulation. CA was added to the melt of Gelucire 50/13,
maintaining a temperature of 60 1C to obtain a clear molten
mixture. The molten mixture was then added drop-wise over a
period of 1 min to Sylysia 350 with continued mixing.
Hot-melt granulation was performed with proper mixing for
15 min to obtain the ternary dispersion granules of CA,
Gelucire 50/13 and Sylysia 350. The dispersion granules were
allowed to cool to room temperature by air-cooling followed
by sieving through mesh No. 18. The composition of disper-
sion granules is shown in Table 2. Batch size of each
formulation was 200 g. The corresponding physical mixture
(PM) of formulation A6 was also prepared by simple physical
mixing.2.8. Solubility measurement of dispersion granules
The solubility of CA and dispersion granules was deter-
mined18. An excess amount of CA, PM and dispersion
granules was added to 20 mL of freshly prepared SGF without
enzyme in clean vials with continuous shaking on a mini
rotary shaker at 2570.5 1C for 24 h to achieve equilibrium.
The ﬁltered solutions were suitably diluted and analyzed
spectrophotometrically.
Table 2 Composition and solubility data of CA dispersion granules containing different ratios of CA, gelucire 50/13 and
sylysia 350.
Formulation Ratio of composition of dispersion granules Solubilitya (mg/mL)
CA Gelucire 50/13 Sylysia 350
CA 1 – – 0.41270.07
A1 1 0.25 0.125 0.49470.08
A2 1 0.5 0.25 0.72770.04
A3 1 0.75 0.375 1.05270.03
A4 1 1 0.5 1.67370.04
A5 1 1.25 0.625 2.13470.07
A6 1 1.5 0.75 3.96470.02
A7 1 1.75 0.875 4.00670.06
A8 1 2 1 4.01770.06
PM 1 1.5 0.75 0.56770.08
aAll values are expressed as mean7SD, n¼6.
Table 3 Composition of CA tablets with different amounts of excipients.
Formulation
(mg/tablet)
Composition of dispersion granules Crosspovidone Avicel PH 102 Magnesium stearate Aerosil Total weight
CA Gelucire 50/13 Sylysia 350
A9 125 187.5 93.75 0 34.75 4.5 4.5 450
A10 125 187.5 93.75 4.5 30.25 4.5 4.5 450
A11 125 187.5 93.75 9 25.75 4.5 4.5 450
A12 125 187.5 93.75 13.5 21.25 4.5 4.5 450
A13 125 187.5 93.75 18 16.75 4.5 4.5 450
A14 125 187.5 93.75 22.5 12.25 4.5 4.5 450
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Dispersion granules (A6) showing maximum solubility were
subjected to measurement of densities (bulk and tap densities),
angle of repose, Carr’s index and Hausner’s ratio, determined
as per standard procedures19.2.10. Powder X-ray diffraction study (PXRD)
PXRD patterns were obtained at room temperature using a
X’Pert PRO MPD (PANalytical, the Netherlands) with a Cu
anode and a graphite monochromator, operated at a voltage
of 35 kV and a current of 20 mA. The samples were analyzed
in the 2y angle range of 5–501, and the process parameters
were set as scan-step size of 0.021 (2y) and scan-step time of
25 s.2.11. Preparation of tablets
Accurate amounts of crosspovidone, Avicel PH 02, magne-
sium stearate, and Aerosil (Table 3) were mixed with disper-
sion granules (A6) in a poly bag for 10 min and were then fed
into the die of an instrumented pellet press (KP, Kimaya
Engineers, India) to produce tablets. A punch of 10 mm
diameter, with a dwell time of 2 s and a compaction pressure
of 0.5 t was applied for tablet preparation.2.12. Quality control tests for tablets
The prepared tablets were subjected to standard quality
control tests. Weight variation was determined by weighing
20 tablets individually, the average weight was calculated and
the percentage variation of each tablet was determined.
Hardness was determined by testing 6 tablets from each
formulation using a Electrolab digital portable hardness tester
EH-01 (Electrolab, India) and the average applied pressure
(kg/cm2) required to crush each tablet was determined.
Friability was determined by ﬁrstly weighing 10 tablets then
placing them in a friability tester EF-2W (Electrolab, India)
which was rotated for 4 min at 25 rpm. After dusting, the total
remaining weight of the tablets was recorded and the percen-
tage of friability was calculated. The disintegration time for
the tablets was determined in 900 mL of distilled water using a
programmable tablet disintegration tester ED-2L (Electrolab,
India).2.13. In vitro dissolution test
The release of CA from dispersion granules (A6), PM, and
tablets (A9-A14) was determined using USP Tablet Dissolu-
tion Tester TDT-06L (Electrolab, India) at 50 rpm. Dissolu-
tion was examined using 900 mL of SGF without enzyme.
The temperature was maintained at 3770.2 1C. Samples each
containing 5 mL were withdrawn at 5, 10, 15 and 30 min time
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(Auroco, Thailand) and replaced with an equal amount of
fresh dissolution medium to maintain sink condition. Samples
were then suitably diluted and analyzed for CA content
spectrophotometrically at 280 nm. The release studies were
conducted in triplicate. The dissolution proﬁles were evaluated
for amount of drug released in the initial 15 min (Q15min).
The percent dissolution efﬁciency (% DE) was also com-
puted to compare the relative performance of various con-
centrations of superdisintigrant in the formulations. The %
DE of a pharmaceutical dosage form is deﬁned as the area
under the dissolution curve up to a certain time, t, expressed as
a percentage of the area of the rectangle described by 100%
dissolution at the same time20. The % DE can be calculated
from
% DE¼
R t
0 Ydt
Y100t
ð3Þ
where Y is the percent drug dissolved at time t.
To understand the extent of CA dissolution-rate enhance-
ment from its formulations, the dissolution data were used to
calculate the mean dissolution time (MDT)21. The MDT can
be calculated by using the following equation:
MDTin vitro ¼
Pn
i ¼ 1
Tmid DM
Pn
i ¼ 1
DM
ð4Þ
where i is the dissolution sample number, n is the number of
dissolution sampling times, Tmid is the midpoint between times
Ti and Ti1, and DM is the amount of CA dissolved between
times Ti and Ti1. Finally Hixson and Crowell’s cubic root law
of dissolution was applied to evaluate the effect of change in
surface area on dissolution rate of all the formulations.
The dissolution related parameters are shown in Table 4.
2.14. Comparison of dissolution proﬁles by a model-
independent method
The model-independent method developed by Moore and
Flanner22 was used to compare dissolution proﬁles using
two factors, f1 and f2. The factor f2, known as the similarity
factor, measures the closeness between the two dissolution
proﬁles and f1, the difference factor, measures the dissimilarity
between two dissolution proﬁles.Table 4 Dissolution parameters of CA, PM and formulations.
Formulation % DE10 % DE20 % DE30
CA 1.56 2.98 3.56
PM 2.61 3.12 3.82
A6 40.42 65.72 6.65
A9 12.82 16.45 22.56
A10 10.56 16.55 20.89
A11 14.66 23.58 29.38
A12 18.75 30.78 36.15
A13 23.78 36.58 44.34
A14 34.54 58.75 73.36
% DE10, % DE20 and % DE30 are the percent dissolution efﬁciency at 1
min and Q15min amount of drug released in initial 15 min.f1 ¼
Pn
t ¼ 1
9Rt Tt9
 
Pn
t ¼ 1
Rt
 
8>><
>>:
9>>=
>>;
100 ð5Þ
f2 ¼ 50 log 1þ ð1=nÞ
Xn
t ¼ 1
ðRtTtÞ2
" #0:5
100g
8<
: ð6Þ
where n is the number of time points, Rt is the dissolution
value of the reference product at time t, and Tt is the
dissolution value of the test product batch at time t.
For curves to be considered similar, f1 values should be close
to 0, and f2 values should be close to 100. Generally, f1 values
up to 15 (0–15) and f2 values greater than 50 (50–100) ensure
sameness or equivalence of the two curves and, thus, of the
performance of the test (postchange) and reference
(prechange) products. In the present research, a dissolution
proﬁle of dispersion granules (A6) was compared with tablet
formulation (A14).
2.15. Stability studies
Strip packed and unpacked tablet samples of the formulation
A14 were subjected to stability studies for a period of
6 months as per ICH guidelines at the ambient temperature
and relative humidity and 40 1C/75% RH conditions in a
humidity-controlled oven (TH90 S/G, Thermolab, India). The
samples (strip-packed and unpacked) were withdrawn at 0, 1,
2, 3 and 6 months for all temperature conditions and
evaluated for appearance, drug content and in vitro drug
release at 30 min.
Tablet samples of the formulation A14 were subjected to
stability studies for a period of 6 months as per ICH guidelines
at 40 1C and 75% RH conditions using a humidity-controlled
oven (TH90 S/G, Thermolab, India). The samples were with-
drawn at 3 and 6 months and evaluated for effect of storage
on drug polymer interactions by DSC study.
2.16. Antimicrobial efﬁcacy
For the purpose of this study, the antimicrobial activity of
formulation A14, marketed tablet and placebo tablet was
evaluated. Each experiment was carried out in triplicate.MDT (min) Q15min Hixson Crowell’s (r
2)
27.6 3.6 0.9721
25.34 3.8 0.9734
5.59 94.5 0.9932
8.97 18.4 0.9674
7.11 19.3 0.9771
7.05 32.8 0.9818
6.59 48.7 0.9858
6.34 58.7 0.9937
5.97 92.4 0.9970
0, 20 and 30 min, respectively; MDT is the mean dissolution time in
Table 5 Inhibition of growth of in vitro dissolution samples against Escherichia coli.
Time (min) Mean zone diameter (mm) Cu. Percent drug release derived from
zone of inhibition data (A14)(%)
Optimized formulation A14 Placebo Marketed formulation
5 0.8170.01 0 0.3770.01 57.54
10 0.9770.02 0 0.5470.02 71.23
15 1.1270.02 0 0.6370.03 82.34
30 1.35þ0.02 0 0.7270.02 99.25
0: No zone of inhibition, mean zone diameter are expressed as mean7SD, n¼3.
Jammula Sruti et al.118For the formulation A14 samples collected from the in vitro
release study of formulation A14, marketed tablet and placebo
tablet at different time intervals (5, 10, 15 and 30 min) were
tested against Escherichia coli ATCC25922, the most com-
monly found organism in patients with bacterial infections
and urinary tract infections. CA (pure drug) at different
concentrations in SGF without enzyme (0, 0.25, 0.5, 1, 2, 4,
8, 16 and 32 mg/mL) was also tested against the same strains.
Molten agar media was transferred to sterilized petri dishes
and allowed to solidify. The plates were swabbed with the
culture of the microorganism. Wells equidistant from one
another were made in the solidiﬁed medium using a sterilized
well borer. The 100 mL samples collected from the in vitro drug
release aliquots from dissolution of formulation A14, mar-
keted tablet and placebo and were ﬁltered through a 0.45 mm
nylon ﬁlter and carefully transferred into the wells. Samples
were allowed to diffuse for 2 h at room temperature. The
plates were then incubated for 48 h at 3770.5 1C23. The
diameter (mm) of zone of growth inhibition surrounding each
agar well was measured using a caliper as described in Table 5.
Figuer 1 Fourier transform infrared spectrograms of pure drug
cefuroxime axetil (CA), formulation A6 and the corresponding
physical mixture (PM).
Figure 2 Differential scanning calorimetric thermograms of
cefuroxime axetil (CA), Gelucire 50/13, formulation A6 and the
physical mixture (PM).3. Results and discussion
3.1. FT-IR spectroscopy studies
Infrared spectra of CA as well as its ternary dispersion
granules are presented in Fig. 1. CA alone shows two carbonyl
absorption bands at 1681 cm1, assigned to amide carbonyl
stretching. There were two absorption peaks at 3483 cm1 and
1778 cm1, assigned to secondary N–H stretching vibration
and a CQO stretching of a vinyl ester, respectively, all of
which remained unchanged in dispersion granules. Hence,
there is no interaction between CA and excipients used in the
present research.
3.2. Differential scanning calorimetry (DSC)
Fig. 2 represents the DSC thermograms of CA, Gelucire 50/13,
PM of corresponding formulation A6 and solid dispersion of
CA (formulation A6). The DSC thermogram of CA exhibited
a broad exothermic peak at 237.71 1C (Tfus), with onset at
202 1C and latent heat of fusion (DHfus) was found to be
49.92 mJ, indicating the amorphous nature of the drug,
whereas the DSC thermogram of PM exhibited a broad
exothermic peak at 241.67 1C. However, the DSC thermo-
grams of solid dispersion A6 showed an exothermic peak at
221 1C with a latent heat of fusion (DHfus) value of 8.9 mJ,
clearly indicating the formation of a solid dispersion and drug
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have formed a complex in the carrier during thermal
analysis24.
3.3. Analytical method
The standard curve prepared for the determination of drug
concentration in samples was linear (Y¼0.038Xþ0.001) in the
concentration range of 5–40 mg/mL with R240.999. Absor-
bance of samples was measured spectrophtometrically using
SGF without enzyme as blank.
3.4. Phase solubility study
The phase-solubility diagram determined in distilled water was
linear (R2¼0.984) with respect to the increase in the weight
fraction of the Gelucire 50/13 (2–10%, w/v), indicating the
solvent properties of Gelucire 50/13 for CA, giving AL-type
solubility. The values of the stability constant depend on the
slope values. The greater the value of the slope, the greater is
the capacity of the polymer to solubilize the drug. The stability
constant values vary slightly with Gelucire 50/13 concentra-
tion. These results agree with the well-established formation of
soluble complexes between water-soluble polymeric carriers
and poorly water-soluble drugs25. Increased solubility may be
due to the improved wettability of the CA particles in the
aqueous solution of Gelucire 50/13. The Gibbs free energy
DGtr1 values are all negative for Gelucire 50/13 at various
concentrations (Table 1), indicating the spontaneous nature of
solubilization26. Gibbs free energy decreased with increases in
the concentration of Gelucire 50/13 demonstrating that the
reaction became more favorable as the concentration of
Gelucire 50/13 increased.
3.5. Conformational analysis by molecular modeling
The molecular modeling revealed that a deﬁnitive energy
minimization was possible for drug and drug–polymer com-
plex. Total potential energy without complexation for CA and
Gelucire 50/13 was 277.979 kcal/mol and 1638.821 kcal/mol
respectively. Fig. 3a and b depicts the energy-minimized
structure of pure drug (CA) and Gelucire 50/13. It has been
conﬁrmed that there is the possibility for formation of a
complex between drug and polymer as evident from the
energy-minimized structure of the drug–polymer complex asFigure 3 Energy minimized structures of (a) cefuroxime axetil, (b) Grepresented in Fig. 3c. The drug molecule was able to bind
with polymer at the free alkyl groups by formation of
hydrogen bonding. It has been observed that the total
potential energy of CA (70.5626 kcal/mol) was reduced to
33.5789 kcal/mol after complexation with Gelucire 50/13,
which corresponds with solubility enhancement. Further, the
decrease in potential energy corroborates a more stable nature
of the drug–polymer complex17.
3.6. Preparation of dispersion granules
Dispersion granules were prepared under similar conditions.
The melt-dispersion of CA with Gelucire 50/13 alone adhered
to the wall of container after drying. This led to a reduced
yield of the product with poor ﬂowability. Addition of a
molten mixture of CA and Gelucire 50/13 to the porous
carrier Sylysia 350 resulted in adsorption of the molten
mixture. This approach was found to be advantageous for
better yield and ﬂowability of dispersion granules.
3.7. Solubility measurement of dispersion granules
From the solubility data we can infer that there is an 8-fold
increase in the solubility of the drug (Table 2). The improved
solubility of CA in dispersions granules prepared using melt-
dispersion granulation can be explained by the improved
wettability of the CA particles in aqueous solution from
gelucire 50/13. Surfactive power improves the solubility and
wettability of CA27. The solubility of CA increased with an
increase in the ratio of gelucire 50/13:CA up to 1:1.5, and a
further increase in gelucire 50/13 proportion showed nearly
identical solubility. Although dispersion granules have the
potential to enhance the dissolution of poorly water-soluble
drugs, they have some challenging factors such as difﬁculty in
pulverization, poor compressibility and poor ﬂowability.
3.8. Flowability and compressibility
The values of angle of repose (211), C.I. (14%) and H.R. (1.21)
for dispersion granules (A6) revealed that ﬂowability and
compressibility were within the theoretical range for proces-
sing into tablet dosage form. Initial trial formulations showed
that the dispersion granules of CA and Gelucire 50/13 were
sticky in nature. Addition of Sylysia 350 (50% of the quantity
of gelucire 50/13) in each dispersion granule formulationelucire 50/13 and (c) cefuroxime axetil-Gelucire 50/13 complex.
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granules into ﬂowable dispersion granules which could
be processed into a tablet. This was attributed to the high
oil adsorption capacity and high speciﬁc surface area of
Sylysia 35028.3.9. Powder X-ray diffraction study (PXRD)
The PXRD patterns of CA, Gelucire 50/13 and PM of
corresponding formulation A6 and dispersion granules (for-
mulation A6) are depicted in Fig. 4. The XRD pattern of CA
showed the absence of signiﬁcant sharp peaks indicating that
the drug is in an amorphous state, which is in agreement with
DSC. The diffraction pattern of Gelucire 50/13 exhibited
intensity peaks at 2y values of 19.481, 21.171 and 23.971.
However, the XRD pattern of dispersion granules of formula-
tion A6 exhibited the characteristic reduced intensity of peaks
for Gelucire 50/13 due to presence of Sylysia 350 (Fig. 4).
The presence of Sylysia 350 could inhibit the reversion of the
amorphous drug to a crystalline state on storage of the solid
dispersion29. This conﬁrmed that the CA is present in the
amorphous state in the solid dispersion, and that there was no
chemical interaction of CA with the excipients used30.
The amorphous nature of CA in the prepared dispersion
granules ratiﬁed the solubility-enhancement potential of exci-
pients used for preparation of dispersions granules.3.10. Preparation of tablets
Tablets were prepared under similar conditions using a pellet
press (KP, Kimaya Engineers, India). The prepared tablets
from the optimized solid dispersion granules were found to be
ﬂat, circular and shiny. Tablets prepared from dispersion
granules (A6) slightly adhered to the surface of the upper
punch but incorporation of aerosil and magnesium stearate
solved this problem. A dwell time (2 s) was found to be
optimum for producing tablets to meet the desired speciﬁca-
tions for tableting.Figure 4 Powder X-ray diffraction patterns of cefuroxime axetil
(CA), Gelucire 50/13, formulation A6 and corresponding physical
mixture (PM).3.11. Quality control tests for tablets
Drug content values (95–98.6%) demonstrated uniform mix-
ing of CA, Gelucire 50/13, Sylysia 350 and other excipients.
Hardness of the tablets was in the range of 4.2 kg/cm2 to
5.2 kg/cm2. This reveals that the required compressibility was
imparted by Sylysia 350 and Avicel PH 102. Gelucire 50/13 is
a waxy material and tends to stick to the punches during
compression. This problem was resolved by incorporating
magnesium stearate and aerosil as shown in Table 2. Friability
values were in the range of 0.28–0.43%, which ensures no loss
of material from the surface or edge of tablets. This may be
attributed to the waxy nature of Gelucire 50/13. All the
formulations passed the weight variation test which is an
indication of good ﬂowability. Formulation A10 showed a
disintegration time of 22 min. As the proportion of cross-
povidone increased from 1% to 5% per tablet, i.e., from
formulation A10–A14, the disintegration time decreased from
22 to 6.4 min. Crosspovidone produces quick disintegration
because of high capillary activity and pronounced hydration
capacity, with little tendency to form gels31. But it was
observed that Gelucire 50/13-based tablets did not disintegrate
like conventional tablets; rather they erode and ﬂakes are
produced.
3.12. In vitro dissolution test
As shown in Fig. 5, the dissolution proﬁle of CA alone and
that of the physical mixture with a composition equal to that
of formulation A6 is almost similar. This suggests that simple
addition of Gelucire 50/13 in the dissolution medium does not
enhance the dissolution of the drug. However, dissolution of
the drug is enhanced signiﬁcantly from the dispersion granules
(A6). The observed enhancement may be attributed to the
effects of solid dispersion and surface adsorption. Gelucire 50/
13 has an HLB value of 13 and is expected to solubilize the
hydrophobic drug CA in solid state. The simultaneous
presence of Sylysia 350 increases the effective surface area
over which the drug is spread leading to rapid desorption of
drug with exposure to the dissolution medium13.
It appears that compression of formulation A6 into tablets,
i.e., formulation A9, results in a decreased dissolution rate.
This may be attributed to decreased wettability due to pore-
ﬁlling, resulting in slow disintegration of the tablet.Figure 5 In vitro dissolution proﬁle of pure cefuroxime axetil
(CA), physical mixture (PM), solid dispersions (A6) and Tablet
formulations (A9–A14). Results are shown as mean7SD (n¼3).
Figure 6 Differential scanning calorimetric thermograms of
formulation A6 (0 months) and A14 (0, 3 and 6 months) in the
stability study.
Improvement in the dissolution rate and tableting properties of cefuroxime axetil 121We therefore investigated the effect of compression force on
the dissolution performance of the dispersion granules of
formulation (A6). The tablets were prepared using four
different compression forces ranging from 0.25 to 1 t with a
dwell time of 2 s. In the compression range studied, a
signiﬁcant decrease in dissolution rate of tablets was observed.
But when crosspovidone was incorporated in the concentra-
tion range of 1–5% into the tablet formulations (A10–A14),
disintegration time decreased from 23 min to 6.4 min. For-
mulations A6 (dispersion granules) and A14 (5% crosspovi-
done) showed more than 85% drug release in 30 min.
Improvement in the dissolution rate of formulation A14 can
be attributed to disintegration of tablet.
The percent drug released form CA, A6 (Dispersion
granules), corresponding PM, and A14 (Tablet formulation)
at 15 min (Q15min) was found to be 3.6%, 94.5%, 3.8% and
92.4% respectively. The Q15min values showed a 25-fold
increase in dissolution rate at 15 min for formulation A6
and A14. It may be due to retention of the amorphous
structure, improved wettability 32 of the dispersion granules
(A6) and quick disintegration with improved wettability
(A14). The DE10, DE20, and DE30 values are presented in
Table 4. The DE values for CA and PM were signiﬁcantly
lower than formulation A6 and A14. Dissolution onset of A6
was very fast and among the tablet formulations (A10–A14)
A14 had the maximum values of DE10, DE20 and DE30.
Formulation A6 and A14 showed nearly similar dissolution
efﬁciency values. This was due to quick disintegration
(6.4 min) of the tablets. The MDT for CA is 27.6 min; it
decreased to 5.59 and 5.97 min for A6 and A14 respectively.
This suggests that dissolution of CA from these two formula-
tions was faster compared to other formulations. Formulation
A6 and A14 showed more than 85% CA release in 30 min;
hence, tablet formulation A14 is a rapidly dissolving tablet as
per WHO. The correlation coefﬁcient for Hixson Crowell’s
equation was higher for formulation A6, A13 and A14,
suggesting that the rate of dissolution increased with increase
in surface area.
Although both formulations A6 (dispersion granules) and
A14 (tablet formulation) have similar dissolution proﬁles,
tablets are always preferred over dispersion granules. Hence
the dissolution proﬁles of both A6 and A14 were compared by
the model-independent method. The value of f1 was found to
be less than 15 (3.05) which ensure sameness or equivalence of
the two curves. The value of f2 was found to be more than 50
(63) which ensure sameness or equivalence of the two curves.
Thus the performance of the test (postchange) and reference
(prechange) products, i.e., the dispersion granule (A6) and
tablet (A14), was equivalent. Hence formulation A14 was the
optimized tablet formulation with improved dissolution rate.3.13. Stability studies
Stability studies for the strip-packed and unpacked tablets of
formulation A14 did not show any signiﬁcant change in
appearance, drug content and in vitro drug release at 30 min
at Po0.01 level. Hence, the stability study for 6 months
indicates that CA is stable in the presence of Gelucire 50/13,
Sylysia 350 and other excipients.
Fig. 6 represents DSC thermograms of optimized formula-
tion A14 (0, 3 and 6 months of storage at 45 1C with 75%RH). There was no inﬂuence of storage time as well as storage
conditions on the peak temperatures of this drug in the
dispersion granules but a decrease in heat of fusion (DHfus)
was observed for the 6-month sample. Similar studies have
shown no changes in the properties of Gelucire formulations
as a function of time33. Adsorption of melt dispersions onto
the surface of sylysia 350 also help in retaining the amorphous
nature of drugs34.
3.14. Antimicrobial efﬁcacy
Inhibition of growth by pure drug CA solutions at different
concentrations against E. coli was studied. The zone of
inhibition for various concentrations of pure drug CA at 0,
0.25, 0.5, 1, 2, 4, 8, 16 and 32 mg/mL was found to be 0, 0, 0,
0.12, 0.21, 0.42, 0.71, 1.80 and 3.13 mm, respectively. It was
observed that the minimum concentration of drug required for
demonstrating zone of microbial growth inhibition in SGF
without enzyme was 1 mg/mL. The in vitro antimicrobial
activities of the optimized formulation A14, marketed tablet
and placebo tablet were evaluated in SGF without enzyme
against E. coli. In vitro dissolution samples of formulation A14
showed maximum inhibition of growth against E. coli in 15
and 30 min samples. Similar results were also observed for the
dissolution study, i.e., more than 85% CA released within 15–
30 min, indicating a good correlation between zone of inhibi-
tion and cumulative percentage of drug released (Table 5). The
in vitro release samples for placebo formulation showed no
inhibition of growth of the microorganism whereas the
marketed formulation showed lesser inhibition of growth
because of a slower dissolution rate.4. Conclusions
A combination of melt-granulation dispersion and surface
adsorption can be used to enhance the dissolution of the
poorly water-soluble drug CA. Gelucire 50/13 plays a sig-
niﬁcant role in the enhancement of drug solubility and
Jammula Sruti et al.122dissolution. The surface adsorbent, Sylysia 350, may be used
to impart good ﬂow and compressibility to dispersion gran-
ules. Further, Sylysia 350 also improves the dissolution rate by
increasing the effective surface area. The ternary dispersion
granules can be compressed into tablets without processing
problems, which are often associated with tableting of disper-
sion granules.
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